Anebulo Pharmaceuticals, Inc. 8-K

What Happened
Anebulo Pharmaceuticals, Inc. announced on January 29, 2026 the final results of its previously announced cash tender offer to purchase up to 300,000 shares of its common stock at $3.50 per share. The tender offer expired one minute after 11:59 p.m. (New York City time) on January 26, 2026. Broadridge Corporate Issuer Solutions, LLC, the depositary, reported that 4,907,881 shares were properly tendered and not properly withdrawn (the offer was oversubscribed). Anebulo accepted 300,000 shares (including 134,306 odd lots) for payment, for an aggregate purchase cost of approximately $1.05 million, excluding fees and expenses. The final proration factor was 3.47392%. Payment for accepted shares and return of all other tendered shares will occur promptly in cash without interest.

Key Details

• Purchase price: $3.50 per share.
• Shares accepted: 300,000 shares (including 134,306 odd lots).
• Total shares tendered: 4,907,881 (oversubscribed).
• Aggregate cost to Anebulo: ~ $1.05 million (excludes fees/expenses); accepted shares ≈ 0.73% of outstanding shares as of Jan 26, 2026.
• Allocation: odd lots accepted in full; all other tenders accepted on a pro rata basis; final proration factor = 3.47392%.

Why It Matters
This filing confirms Anebulo completed a small, cash-funded repurchase of common stock under a tender offer, reducing shares outstanding by roughly 0.73% and using about $1.05 million in cash. For retail investors, the item is a concrete update on the company’s capital allocation (a buyback execution) and shows the level of shareholder participation at the $3.50 price (the offer was oversubscribed). Payment and return logistics are being handled by the depositary and will be completed promptly.